111, Inc. (YI) 株式分析

企業概要

111, Inc. (YI) operates as a provider of integrated online and offline supply chain solutions within the healthcare ecosystem of the People's Republic of China, serving both retail and wholesale pharmaceutical markets through its distinct B2C and B2B business segments. The enterprise functions within the broader Healthcare sector, specifically the Medical Distribution industry, where its role involves managing the logistics and distribution networks essential for pharmaceutical companies to reach end consumers. As of the latest data, the company possesses a market capitalization of $56.16M, generated an annual revenue of $13.58B, and maintains an organizational structure comprising 1238 employees. These financial metrics collectively indicate a significant operational scale in terms of revenue generation, yet the relatively modest market capitalization suggests that the market values the entity at a fraction of its sales volume, potentially reflecting challenges in profitability or future earnings visibility that constrain its equity valuation relative to its massive top-line turnover.

財務健全性

The company reported a trailing twelve-month revenue of $13.58B alongside a net income of -$70,012,000 and an EBITDA of $3.98M, a disparity that reveals a highly leveraged cost structure where operating expenses and interest costs significantly erode the bottom line before taxes. While the gross margin stands at 2.8%, the operating margin is -0.1% and the profit margin is -0.5%, indicating that the company is currently unable to cover its fixed overheads and non-operating expenses with its gross profits, resulting in a loss on every dollar of sales. The free cash flow stands at -$22,583,250, which signifies a negative liquidity generation from operations that limits the company's financial flexibility to fund capital expenditures or organic growth without external financing. On the balance sheet side, the company holds $493.62M in cash against $204.73M in debt, resulting in a debt-to-equity ratio of 93.56, which points to a highly leveraged position where debt obligations are substantial relative to shareholders' equity. Despite holding more cash than debt, the current ratio of 1.07 indicates that current assets barely exceed current liabilities, suggesting a fragile short-term liquidity position with minimal buffer against working capital demands. Furthermore, the return on equity is -10.9% and the return on assets is -0.2%, metrics that demonstrate management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

バリュエーション評価

The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E stands at 46.29, implying that the market is pricing in a significant turnaround in earnings to justify the current multiple. The price-to-book ratio is -0.57, a figure that indicates the market values the company's equity at a negative premium relative to its book value, a situation often found in distressed or loss-making firms. Alternative valuation measures such as the price-to-sales ratio of 0.00 and an EV/EBITDA of 437.63 further suggest that traditional valuation models based on profitability are not applicable, as the company is trading at a premium relative to its earnings power but generating negligible sales multiples. The stock has exhibited significant volatility, trading between a 52-week high of $11.17 and a 52-week low of $2.48, placing the current price context within a range where the company has recovered substantially from its annual lows but remains well below its recent peaks. The beta of 0.70 indicates that the stock's price volatility is historically lower than the broader market, suggesting it may be less sensitive to general market swings despite its high valuation multiples and negative earnings.

Growth & Income

The company is experiencing a contraction in its top line with a revenue growth rate of -16.7% year-over-year, while earnings growth is listed as N/A due to the continued net losses, meaning there is no positive earnings trajectory to offset the decline in sales volume. As the company does not distribute a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all of its earnings rather than returning capital to shareholders, a strategy necessitated by its current inability to generate net income. The absence of dividend payments confirms that the firm is prioritizing capital preservation or potential future expansion over income distribution, though the negative free cash flow complicates the ability to fund growth internally. Overall, the growth and income profile is characterized by a contraction in revenue, a complete absence of dividend income, and a financial structure that relies heavily on existing cash reserves to navigate a period of negative profitability and declining sales.